International Journal of Radiation Oncology Biology Physics最新文献

{"title":"Radiation Induces Pericyte-Myofibroblast Transition.","authors":"Tomoko Yamazaki, Kelley R Jordan, Nathaniel Fox, Kristina H Young","doi":"10.1016/j.ijrobp.2025.05.083","DOIUrl":"10.1016/j.ijrobp.2025.05.083","url":null,"abstract":"<p><strong>Purpose: </strong>Radiation not only kills cancer cells directly through DNA damage but also indirectly by inducing vascular changes. The effects of radiation on tumor vasculature are critical for therapeutic efficacy; however, its impact on pericytes remains largely unknown. In this study, we investigated the effect of radiation on pericytes and sought to elucidate the mechanism by which radiation affects pericytes.</p><p><strong>Methods and materials: </strong>C3H10T1/2 (10T1/2) mouse embryonic mesenchymal pericyte precursor cells and human pericytes from placenta (hPC-PL) cells were irradiated to study the effects of radiation on pericyte differentiation, maturation, and transition of pericytes into myofibroblasts by flow cytometry, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and immunofluorescence. Phospho-kinase array, Western blot, and reactive oxygen species (ROS) detection assay were conducted to elucidate the signaling pathways activated by radiation in pericytes. To investigate the pericyte-myofibroblast transition in vivo, MC38 tumor cells were implanted in NG2DsRedBAC (NG2DsRed) transgenic mice whose pericytes express DsRed. Tumors harvested 3, 5, and 7 days after radiation were assessed for myofibroblast markers in DsRed⁺ cells.</p><p><strong>Results: </strong>Radiation promoted pericyte differentiation and increased the expression of adhesion molecules in both 10T1/2 and hPC-PL cells. Permeability and leukocyte adhesion were altered by radiation via an effect on endothelial cells, not pericytes. Radiation increased the expression of myofibroblast markers and induced morphologic changes. Phospho-kinase array indicated radiation activates the Akt signaling pathway, and inhibitors of Akt and ROS suppressed the expression of myofibroblast markers increased by radiation. MC38 tumors implanted in NG2DsRed transgenic mice harvested 3 days after radiation exhibited increased expression of myofibroblast markers in DsRed⁺ cells, indicating radiation-induced pericyte-myofibroblast transition in vivo. Administration of an Akt inhibitor in combination with radiation in tumor-bearing NG2DsRed mice reduced vimentin expression in tumors.</p><p><strong>Conclusions: </strong>Our data suggest radiation promotes pericyte maturation and transition into myofibroblasts via Akt signaling.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histologic Classifier of Radiosensitivity to Spine Stereotactic Body Radiation Therapy.","authors":"Christopher B Jackson, Lillian A Boe, Lei Zhang, Aditya Apte, Andrew Jackson, Lisa M Ruppert, Justin Haseltine, Boris A Mueller, Adam M Schmitt, Max Vaynrub, William Christopher Newman, Eric Lis, Ori Barzilai, Mark H Bilsky, Yoshiya Yamada, Daniel S Higginson","doi":"10.1016/j.ijrobp.2025.05.078","DOIUrl":"10.1016/j.ijrobp.2025.05.078","url":null,"abstract":"<p><strong>Purpose: </strong>Spine stereotactic body radiation therapy (SBRT) outperforms conventional radiation therapy in preventing local failure (LF). Data comparing dose-fractionation schemes on the likelihood of LF and vertebral compression fracture (VCF) are limited.</p><p><strong>Methods and materials: </strong>This is a retrospective cohort study of 1838 patients (2702 lesions) treated between 2014 and 2023 at a single institution with de novo spine SBRT. LF was defined as progressive disease on magnetic resonance imaging. VCF was defined as progressive or new fracture on magnetic resonance imaging without LF. Death was considered a competing risk.</p><p><strong>Results: </strong>Median follow-up after SBRT for surviving patients was 25 months (IQR 13-43 months). Twelve hundred one lesions (44%) received 27 Gy in 3 fractions, 931 (34%) received 30 Gy in 3 fractions, and 574 lesions (21%) received 24 Gy in 1 fraction. Three hundred nine treatment courses involved separation surgery (11%), and 311 lesions (11%) were epidural spinal cord compression score 2 to 3. For lesions treated with 24 Gy in 1 fraction, 30 Gy in 3 fractions, and 27 Gy in 3 fractions, 2-year LF rates (95% CI) were 7% (5%-9%), 11% (9%-13%), and 17% (15%-20%), respectively (P < .001). Two-year VCF rates (95% CI) requiring stabilization were 10% (8%-13%; 24 Gy in 1 fraction), 2% (1%-3%; 27 Gy in 3 fractions), and 3% (2%-5%; 30 Gy in 3 fractions) (P < .001). For the 3-fraction regimens specifically, 30 Gy was associated with a higher overall VCF rate (P = .022) and lower LF rate (P < .001), but there was no significant difference in the risk of VCF requiring intervention (P = .15). Univariable and multivariable regression revealed histologic-based differences in LF: 2-year LF rates were 8.6% (95% CI, 6.4%-11%) for class A lesions (prostate and breast cancers), 26% (95% CI, 20%-32%) for class C lesions (cholangio-, hepatocellular, and colorectal carcinoma), and 13% (95% CI, 12%-15%) for class B lesions (other histologies) (P < .001). For class B to C, epidural spinal cord compression 2 to 3 lesions (n = 261), surgery plus SBRT reduced LF compared to SBRT alone (7.9 vs 20% at 2 years, P = .051), though this did not reach statistical significance.</p><p><strong>Conclusions: </strong>The preferred hypofractionated SBRT regimen-even for class A histologies-is 30 Gy in 3 fractions, offering superior local control with similar risk of VCF requiring intervention, compared to 27 Gy. For class B to C lesions with high-grade epidural disease, separation surgery prior to SBRT may improve local control.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Outcomes Following Adjuvant Radiation Therapy in Triple-Negative Breast Cancer Patients With Prior Autoimmune Myocarditis.","authors":"Pierre Loap, Assile El Fakih, Clara Helal, Luc Cabel, Alain Fourquet, Toulsie Ramtohul, Delphine Loirat, Jean-Yves Pierga, François-Clément Bidard, Mariana Mirabel, Youlia Kirova","doi":"10.1016/j.ijrobp.2025.06.3294","DOIUrl":"10.1016/j.ijrobp.2025.06.3294","url":null,"abstract":"<p><strong>Purpose: </strong>Cardiac toxicity during breast cancer treatment can arise from radiation therapy (RT), chemotherapy, and immunotherapy, particularly in triple-negative breast cancer (TNBC). Immune checkpoint inhibitors such as pembrolizumab improve TNBC outcomes but are associated with rare, severe immune-related adverse events, including autoimmune myocarditis. Although RT techniques minimize high-dose cardiac exposure, low-dose exposure may modulate immune activity and potentially reactivate autoreactive T lymphocytes. This study evaluates cardiac events during and after adjuvant RT in patients with TNBC with a history of autoimmune myocarditis.</p><p><strong>Methods and materials: </strong>This retrospective bicentric study included 22 patients with T2-T4 or node-positive TNBC treated with pembrolizumab and chemotherapy that developed autoimmune myocarditis during the neoadjuvant phase. Patients subsequently underwent adjuvant RT following surgery. Cardiac toxicity was monitored via echocardiography and clinical assessments, focusing on ventricular dysfunction and symptoms. The primary endpoint was the incidence of cardiac events during RT, early post-RT (≤6 months), and late post-RT (>6 months). Secondary endpoints included survival and radiation-induced toxicities.</p><p><strong>Results: </strong>The cohort's median age was 49 years, with most tumors classified as T1-T2 (86.3%) or as node-negative (59.1%) before the initiation of chemoimmunotherapy. One patient (4.5%) developed asymptomatic ventricular dysfunction (left ventricular ejection fraction 37% at late evaluation), and 5 patients (22.7%) experienced late-onset symptoms, which could potentially be associated with cardiac etiology, including New York Heart Association class II dyspnea and palpitations, despite normal left ventricular ejection fraction and troponin levels. All potential cardiac events/symptoms occurred after RT, even though pembrolizumab had been discontinued. Radiation dermatitis (59.1%) and dysphagia (13.6%) were the most common noncardiac toxicities. At 2 years, recurrence-free survival was 95%, with no reported deaths.</p><p><strong>Conclusions: </strong>This study highlights the potential for late-onset cardiac events or symptoms in patients with TNBC with prior autoimmune myocarditis treated with adjuvant RT. Although most maintained stable cardiac function, a subset developed late-onset ventricular dysfunction or new symptoms despite low mean heart doses and pembrolizumab discontinuation. These findings warrant further investigation of the etiology, including the possibility that immune modulation from RT plays a role.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pragmatic Patient Choice-Driven Radical Treatment Approach (PRAGRAD) for Very Advanced Unresectable Oral Cavity Cancers.","authors":"Balu Krishna Sasidharan, Sharief K Sidhique, Jino Victor Wilson, Manu Mathew, Amit Jiwan Tirkey, Ashish Singh, Jenifer Jeba Sundararaj, Hannah Mary T Thomas, B Swathi, Benny Rajendra Kuchipudi, Jerome Sunny, Anjana Joel, Annie Jacob, Vidya Konduru, Mansi Agarwal, Aparna Irodi, Jeyashanth Riju, Natarajan Ramalingam, Rajiv Michael, Rajesh Isiah, Anjana Chandran, Sharon Gikku George, C Praveenraj, Andre Dekker, Leonard Wee, Frank Hoebers, Simon P Pavamani","doi":"10.1016/j.ijrobp.2025.05.088","DOIUrl":"10.1016/j.ijrobp.2025.05.088","url":null,"abstract":"<p><strong>Purpose: </strong>The treatment of locally advanced unresectable oral cavity cancers (OCCs) is challenging, with limited consensus on optimal management and poor outcomes. Our clinical practice identified a subset of unresectable OCC patients who respond favorably to aggressive alternate treatment with chemotherapy and radiation therapy. We propose a systematic design for optimal selection method that is patient choice-driven while attempting to managing unresectable OCC with radical therapy approach.</p><p><strong>Methods and materials: </strong>This observational pragmatic patient choice-driven cohort study enrolled patients deemed palliative by the multidisciplinary team. Patients were offered a choice between upfront palliation (cohort UPA) or upfront radical (cohort URAD) treatment. After induction chemotherapy, URAD patients were further stratified as responders (R) or nonresponders (N) and offered a choice between radical chemoradiation therapy (responder radical [RRAD] and nonresponders radical) or palliative treatment (responders palliation [RPA] and nonresponders palliation). We compared the overall survival between the cohorts using the University of Washington quality of life version 4 scores.</p><p><strong>Results: </strong>A total of 103 patients were screened and 73 enrolled with buccal mucosa 37 (49%) and oral tongue 26 (36%) being major sites; majority 57 (78%) chose URAD and UPA included 16 (22%) patients. After induction chemotherapy, 35 (65%) patients were responders. Of these, 27 (77%) opted to continue radical treatment (RRAD) and 8 (23%) chose palliation (RPA). Among the nonresponders (n = 19), 8 (42%) opted for radical treatment (nonresponders radical) and 11 (58%) chose palliation (nonresponders palliation). Overall, quality of life scores for URAD improved significantly from baseline to postintervention (30-60; P < .05), compared with the UPA (17-25; P = .75) with pain scores being the best in URAD (26-80; P < .05). Following stratification, the RRAD cohort showed median overall survival of 37.9 (95% CI, 18.4-not reached) and RPA was 14.0 (5.0-15.0) months compared with UPA 6.0 (3.0-9.0) months.</p><p><strong>Conclusions: </strong>The study assessed the feasibility or futility of managing unresectable OCCs with radical approach instead of palliation. The proposed patient choice-driven stratification protocol showed significantly better quality of life in patients who were optimally selected to undergo aggressive treatment compared with palliative management, with a possible improved survival of at least 9 months.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Once-Daily Postmastectomy Radiation Therapy Confers Excellent Locoregional Control for Inflammatory Breast Cancer.","authors":"Kate R Pawloski, Amy Xu, Brian Diskin, Varadan Sevilimedu, Jacqueline Bromberg, Simran Malhotra, Atif J Khan, Monica Morrow, Audree B Tadros","doi":"10.1016/j.ijrobp.2025.05.075","DOIUrl":"10.1016/j.ijrobp.2025.05.075","url":null,"abstract":"<p><strong>Purpose: </strong>For patients with cT4dM0 inflammatory breast cancer (IBC), improved locoregional control has been reported following modern trimodality therapy that includes hyperfractionated/twice-daily postmastectomy radiation therapy (PMRT). We evaluated survival outcomes in a contemporary cohort of patients with IBC routinely treated with once-daily PMRT.</p><p><strong>Methods and materials: </strong>We retrospectively identified 213 patients with stage III IBC treated with neoadjuvant systemic therapy, modified radical mastectomy, and PMRT from January 2006 to December 2022 at a single institution. Routinely, PMRT included 50 Gy in 18 to 25 daily fractions to the chest wall and regional nodes with a 0.5 to 1.0 cm skin bolus. We calculated the crude rate of isolated locoregional recurrence (LRR) and estimated disease-free survival (DFS) rates using Kaplan-Meier survival curves and a Cox proportional hazard regression model.</p><p><strong>Results: </strong>Median follow-up was 3.5 years (IQR, 1.8-6.3 years). Isolated LRR was observed in 1.8% (4/213) of patients at a median of 10.6 months (IQR, 8.8-18.4 months). LRR with or without a distant failure occurred in 22 patients (10.3%). All LRRs were observed in patients who did not achieve pathologic complete response (pCR) (n = 148). Distant metastasis occurred in 32% (69/213) of patients, and 57 deaths were recorded. On multivariable analysis, triple-negative subtype (hazard ratio [HR], 3.16; 95% CI, 1.56-6.41; P = .001), lobular histology (HR, 2.45; 95% CI, 1.10-5.45; P = .027), and nodal pCR (HR, 0.27; 95% CI, 0.15-0.49; P < .001) were associated with DFS rates. Subgroup analysis demonstrated no difference in DFS rates between biologic subtypes in patients with pCR (P = .29).</p><p><strong>Conclusions: </strong>Once-daily PMRT confers excellent locoregional control in patients with IBC, as evidenced by low rates of isolated LRR at 3.5 years of follow-up. The worse overall LRR and DFS rates observed in patients with triple-negative subtype and residual nodal disease indicate a need to consider escalating local therapy with a boost while also emphasizing the necessity for novel systemic therapies for IBC.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage Therapy for Isolated Local-Regional Breast Cancer Recurrence.","authors":"J Isabelle Choi, Danielle Rodin, Rima Patel, Joseph A Sparano, Atif J Khan, Naamit K Gerber","doi":"10.1016/j.ijrobp.2025.05.077","DOIUrl":"10.1016/j.ijrobp.2025.05.077","url":null,"abstract":"<p><p>The overall number of breast cancer patients at risk of developing local-regional disease recurrence has been increasing due to long-term survivorship from improvements in multimodality breast cancer treatment and a steady increase in breast cancer incidence. Many patients receive radiation therapy as part of definitive multidisciplinary breast cancer treatment, and to date, practitioners have approached reirradiation delivery with reticence due to concern for serious toxicities that may be incurred with high cumulative radiation doses. However, a subset of patients with breast cancer recurrence may benefit from reirradiation for improved locoregional tumor control. An emerging body of evidence has demonstrated promising efficacy and safety of breast cancer reirradiation that is gradually redefining the treatment paradigm. In addition, an increase in systemic therapy options has further optimized the opportunity for successful salvage of breast cancer recurrence. In this critical review, we review breast cancer radiation and systemic therapy salvage options, available data, ongoing studies, and treatment delivery considerations.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Proton FLASH Radiation Therapy: Innovations, Techniques, and Clinical Potentials.","authors":"Yangguang Ma, Tengda Zhang, Balaji Selvaraj, Jiajian Shen, Shouyi Wei, Chingyun Cheng, Hao Gao, Per Rugaard Poulsen, Heng Li, Eric Diffenderfer, Jan Schuemann, Liyong Lin, Zachary Morris, Benjamin Durkee, Jürgen Hesser, Haibo Lin, Charles B Simone, Minglei Kang, Hui Wu","doi":"10.1016/j.ijrobp.2025.05.076","DOIUrl":"10.1016/j.ijrobp.2025.05.076","url":null,"abstract":"<p><p>Proton FLASH radiation therapy (RT) is an emerging technique that offers highly conformal doses similar to conventional intensity modulated proton therapy but with the added potential benefit of protecting organs at risk through the FLASH-sparing effect. This review examines recent advancements in proton FLASH-RT, including transmission beams (TB), single-energy Bragg peak, single-energy spread-out Bragg peak, hybrid FLASH, and multiple-energy spread-out Bragg peak. These proton FLASH technologies are discussed in detail, highlighting their advantages, limitations, and dosimetric comparisons with intensity modulated proton therapy and other FLASH techniques. Although TB achieves dose conformity through multifield optimization, it also has unnecessary exit doses. In contrast, single-energy Bragg peak and single-energy spread-out Bragg peak offer improved organ at risk protection and superior target conformity at the cost of using range compensators and/or ridge filters. Additionally, hybrid FLASH-RT combines TB and Bragg peak methods to target the tumor core and edges separately, whereas multiple-energy spread-out Bragg peak FLASH leverages ultra-fast energy switching. Despite these advancements, only nonconformal TB FLASH-RT has been applied clinically with single fields for palliative RT because of the complexity of other methods and uncertainties about the FLASH effect. This review summarizes the technical details of these FLASH-RT methods and discusses their utilization across various anatomical sites.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapt or Perish: The Heavy Lift of Conducting Trials of Magnetic Resonance Imaging Guided Online Adaptive Radiation Therapy","authors":"Luca F. Valle MD ,&nbsp;Michael L. Steinberg MD ,&nbsp;Amar U. Kishan MD","doi":"10.1016/j.ijrobp.2024.11.080","DOIUrl":"10.1016/j.ijrobp.2024.11.080","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"122 3","pages":"Pages 551-553"},"PeriodicalIF":6.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Battling the Beast of Aggressive Maxillary Sinus Tumors","authors":"Irene Karam MDCM, FRCPC,&nbsp;Lee Chin PhD, MCCPM","doi":"10.1016/j.ijrobp.2025.02.025","DOIUrl":"10.1016/j.ijrobp.2025.02.025","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"122 3","pages":"Page 535"},"PeriodicalIF":6.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144223585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response-Adaptive Radiation Therapy: Toward Precision Radiation in Neuro-Oncology","authors":"Michelle M. Kim MD ,&nbsp;Theodore S. Lawrence MD, PhD ,&nbsp;Yue Cao PhD","doi":"10.1016/j.ijrobp.2025.03.064","DOIUrl":"10.1016/j.ijrobp.2025.03.064","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"122 3","pages":"Pages 558-560"},"PeriodicalIF":6.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}